Arcutis Biotherapeutics Inc (NASDAQ:ARQT) announced new safety and efficacy durability data from its open-label Phase 2 long-term safety study of roflumilast…
Senti Biosciences Inc, the synthetic biology play helmed by MIT whiz Tim Lu, will be merging with Farokhzad's Dynamics Special Purpose Corp (NASDAQ: DYNS) in a